Mediators of Chronic Allograft Rejection and DNA Molecules Encoding Them
Summary This invention provides methods of detecting and treating arterial inflammatory disease, including chronic allograft rejection subsequent to organ transplantation or chronic vascular Chlamydia pnuemonii infection, that results in atherosclerosis or restenosis.
A major limiting factor for survival after organ transplantation is the development of chronic rejection due to obliterative arteriosclerosis in the transplanted blood vessels. The factors responsible for the intimal thickening that characterizes this process have been identified by the inventors and may be used for diagnostic or therapeutic purposes. The accumulation of arterial plaque in coronary arteries as the result of an inflammatory process due to injury or insult appears to involve the same cellular processes.
Applications Identification of the factors involved in chronic transplant rejection and atherosclerosis creates the opportunity to develop a highly specific tissue assay that would positively diagnose either condition from the small amount of tissue retrieved by standard biopsy techniques. Such a clinical diagnostic assay does not currently exist. Development requires clinical validation by the licensee.
Type of Offer:
« More Pharmaceutical Patents« More Diagnostic Patents